Logo

Merck KGaA Signs an Exclusive Worldwide License Agreement with Day One for Pimasertib and MSC2015103B

Share this

Merck KGaA Signs an Exclusive Worldwide License Agreement with Day One for Pimasertib and MSC2015103B

Shots:

  • Merck KGaA to receive up front- additional regulatory- approval- and sales milestone along with royalties on sales of pimasertib and MSC2015103B. The agreement broadens Day One’s clinical-stage pipeline of targeted cancer therapies with the additions of MEK inhibitors
  • Day One plans to initiate a P-I/II study to evaluate the safety- tolerability- and preliminary efficacy of pimasertib in combination with DAY101 in patients aged ≥12yrs. with advanced solid tumors with MAPK inhibitors
  • Pimasertib and MSC2015103B are oral- highly-selective MEK I/II inhibitors. Pimasertib has been studied in 10+ P-I/II studies in ~900 patients with various tumor types

 ­ Ref: Businesswire | Image: Merck KGaA

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions